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Background: Neoadjuvant treatment plays a crucial role in the therapy of advanced esophageal cancer. However,
response to radiochemotherapy varies widely. Proton pump inhibitors (PPIs) have been demonstrated to impact on
chemotherapy in a variety of other cancers. We analyzed the impact of PPI treatment on esophageal cancer cell
lines, and investigated mechanisms that mediate the effect of PPI treatment in this tumour.
Methods: We investigated the effect of esomeprazole treatment on cancer cell survival, adhesion, migration
and chemotherapy in human adeno-(OE19) and squamous-cell-carcinoma (KYSE410) cell lines. Furthermore, we
investigated the effect of PPI treatment on intra-/extracellular pH and on expression of resistance-relevant miRNAs.
Results: Esomeprazole significantly inhibited tumour cell survival (in a dose-dependent manner), adhesion and
migration in both tumour subtypes. Furthermore, esomeprazole augmented the cytotoxic effect of cisplatin and
5-FU in both tumour subtypes. Surprisingly, PPI treatment led to a significant increase of intracellular pH and a
decrease of the extracellular pH. Finally, we found esomeprazole affected expression of resistance-relevant miRNAs.
Specifically, miR-141 and miR-200b were upregulated, whereas miR-376a was downregulated after PPI treatment in
both tumour types.
Conclusion: Our study demonstrates for the first time that PPIs impact on tumour cell survival, metastatic potential
and sensitivity towards chemotherapy in esophageal cancer cell lines. Furthermore, we observed that in this
tumour entity, PPIs do not lead to intracellular acidification, but affect the expression of resistance-relevant miRNAs.
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Esophageal cancer is one of the most fatal malignancies
in the world, with a dramatic increase in incidence in
the western world, especially of the adenocarcinoma
subtype [1]. Despite improvements in the management
of esophageal cancer patients, the general outcome re-
mains very poor for both histological subtypes, with an
overall 5-year survival of approximately 10% and a 5-
year post-esophagectomy survival rate of approximately* Correspondence: richard.hummel@ukmuenster.de
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unless otherwise stated.15-40% [2,3]. The main reason lies in the lack of early
clinical symptoms, which usually results in advanced
tumour stages at the date of diagnosis. In an attempt to
improve outcome of patients after surgery, and to poten-
tially increase the number of patients who qualify for
surgery by reducing the size of the primary tumour, neo-
adjuvant therapy is used. Several recent meta-analyses
have demonstrated the potential of neoadjuvant therapy
in advancing overall survival for both histological sub-
types, particularly for therapy responders. Additionally,
tumour reduction and nodal “down-staging” were de-
scribed as independent prognostic factors for better out-
come after neoadjuvant therapy [3-9]. Furthermore, inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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showed good results, with complete tumour regression
in up to 50% of patients and partial response in ap-
proximately 25% of patients. Therefore, cisplatin- and
5-fluorouracil (5-FU)-based chemotherapy in combin-
ation with irradiation has become part of standard treat-
ment in neoadjuvant, definitive and palliative settings in
most parts of the world [10-12].
However, the resistance of tumours to anticancer drugs
such as cisplatin or 5-FU is a major obstacle in the non-
surgical anticancer treatment of esophageal cancer. One
potential mechanism that confers chemotherapy resis-
tance is disruption of the pH gradient. Hypoxic conditions
in tumour cells are often observed during the deve-
lopment of solid tumours, leading to intracellular and
extracellular acidosis [13]. This change of intra- and
extracellular pH may impair the uptake of weakly basic
chemotherapeutic drugs and reduce their effects on tu-
mours [13-15]. Recent studies demonstrated that pro-
ton pumps such as vacuolar adenosine triphosphatases
(V-ATPases) are involved in tumour invasion and multi-
drug-resistance in breast cancer [16,17], oral squamous
cell carcinoma [18,19], hepatocellular carcinoma [20],
pancreatic cancer [21] and prostate cancer [22]. Fur-
ther, there is accumulating evidence in the literature
that chemotherapy resistance of various tumours can
be reduced via so called proton pump inhibitors (PPIs)
that disrupt the pH gradient by inhibition of proton
pumps [23-25]. PPI pretreatment has been shown to sen-
sitize various cell lines derived from primary tumours, in-
cluding colon and ovarian adenocarcinomas, to cisplatin,
5-FU and vinblastine [26]. Most interestingly, there is
some evidence suggesting that high concentrations of PPIs
alone can induce apoptosis in gastric and hepatoblas-
toma cancer cell lines but not in non-tumourous pri-
mary cells [27,28].
However, to the best of our knowledge, there is no
data available on PPIs as potential antitumour agents or
modulators of drug resistance in esophageal cancer. In
this context, we were interested if proton pump inhibi-
tors such as esomeprazole might potentially serve as a
new first-line drug or as an additive to currently avail-
able chemotherapeutics in the treatment of esophageal
cancer. Specifically, we aimed to investigate 1) if PPI
treatment impacts on tumour cell survival, metastatic
potential and drug resistance of esophageal squamous
cell carcinoma and adenocarcinoma cell lines, and if yes:
2) which cellular mechanisms mediate the effect of PPIs
on tumour cells.
Methods
Cell lines and cell cultures
The human esophageal squamous cell carcinoma (SCC) cell
line KYSE410 and the human esophageal adenocarcinoma(EAC) cell line OE19 were selected for our study. Cells
were cultured using RPMI 1640 medium (GIBCO® Invi-
trogen, #11875), supplemented with 10% fetal bovine
serum (GIBCO® Invitrogen, #26140), 1% Penicillin-
Streptomycin (GIBCO® Invitrogen, #15140; 10.000 units
of penicillin and 10.000 μg of streptomycin per ml) and
2% Normocin™ (InvivoGen, San Diego USA, Catalog #
ant-nr-1; 50 mg/ml) in a humidified atmosphere contain-
ing 5% CO2 at 37°C. For functional assays and chemothe-
rapy experiments, phenol red free medium (RPMI 1640:
GIBCO® Invitrogen, #11835) containing the same supple-
ments were used. Cells were cultured using standard tech-
niques and reagents [10,29]. All experiments were carried
out in at least 3 technical replicates and 3 independent ex-
periments unless otherwise stated.
Proton pump inhibitor treatment with esomeprazole for
functional analyses
For viability assays, cells were plated onto 96-well plates
and allowed to attach for 24 hours (SCC) or 48 hours
(EAC). Then, phenol red free medium containing eso-
meprazole (Nexium®, AstraZeneca, Germany) at various
concentrations was freshly prepared and added to the
corresponding cells. After 72 hours, cell viability assays
were performed as described below.
For adhesion and migration assays, cells were incuba-
ted in T75 flasks for 72 hours with esomeprazole at the
approximate median lethal doses (LD50, as estimated
from cell viability experiments). Adhesion and migration
assays were then performed as described below.
For chemotherapy experiments, cells were treated for
72 hours with either esomeprazole alone at different
concentrations (50 μM: “sub-lethal”, 86-100% cell sur-
vival; 250 μM: “lethal”, 20-30% cell survival; 350 μM:
“highly lethal”, <10% cell survival), or with cisplatin or
5-fluorouracil at the LD50 concentrations, or with
esomeprazole and chemotherapeutics together.
For experiments on the effect of PPI treatment on
intra- and extracellular pH/proton concentrations or on
miRNA expression, cells were incubated for 24/48/72 re-
spectively 72 hours with esomeprazole at the approxi-
mate LD50 dosis (as estimated from cell viability
experiments). Experiments were then performed as de-
scribed below.
Cell viability assay
Cell viability was assessed using MTT (Thiazolyl Blue
Tetrazolium Bromide, Sigma-Aldrich, St. Louis, USA:
no. M2128). 100 μl MTT solution (1 mg/ml MTT in cell
culture medium) was added per well. After three hours,
the supernatant was removed and the MTT formazan
crystals were solubilized for 30 minutes in 100 μl dimethyl
sulfoxide (Sigma-Aldrich) per well. Finally, the absor-
bance at 570 nm was measured on the spectrophotometer
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ware MikroWin 2000 (Mikrotek Laborsysteme, Overath,
Germany).
Adhesion assay
Cells in T75 flasks were incubated for 72 hours with
esomeprazole at the approximate LD50 dose, and subse-
quently underwent a 75 minute starving period using
serum free medium. Cells were trypsinized and incu-
bated for 90 minutes for reconstitution, then cells were
transferred to 96-well plates coated with collagen type I
and fibronectin. These cells were plated under the sti-
mulation of TGF-β2, and cellular adhesion was assessed
after 15/30/60/90 minutes under the photospectrometer
using crystal violet staining. One experiment was per-
formed with 4 technical replicates, and confirmed with
another independent experiment.
Migration assay
Cells in T75 flasks were incubated for 72 hours with
esomeprazole at the approximate LD50 dose, and subse-
quently underwent a 3 hour starving period using serum
free medium. They were plated onto the upper cham-
ber of a 24-well Boyden chamber coated with collagen
type I and/or fibronectin (Corning B.V. Life Sciences,
Amsterdam, The Netherlands; Cat. No. 3428) with an
8-μm pore polycarbonate membrane in medium without
serum, and medium containing 10% fetal bovine serum
was filled in the lower chamber as chemoattractant.
After 12 hours, cells that did not migrate through the
pores were removed using cotton swabs. Membranes
were stained using crystal violet, and migrating cells
were counted in 9 gridded high-power fields per mem-
brane under an inverted microscope. One experiment
was performed with 3 technical replicates, and con-
firmed with another independent experiment.
Chemotherapeutic treatment
Cells were seeded onto 6-well plates (9.5×104 viable
cells/well for KYSE410 and 2×105 viable cells/well for
OE19) and allowed to attach. After reaching 10-20%
confluence, fresh medium containing EITHER no PPI
and chemotherapeutics OR esomeprazole or chemother-
apeutics alone OR esomeprazole and chemotherapeutics
together was prepared and added to the corresponding
cells. Regarding the different esomeprazole doses used in
these experiments please see above. The concentrations
of chemotherapeutics used represented the approximate
LD50 doses after 72 hour exposure (OE19: 25 μM cis-
platin, 20 μM 5-FU; KYSE410: 7.5 μM cisplatin, 20 μM
5-FU; determined in previous experiments, data not
shown). After 72 hour exposure, cell viability assays were
performed as described above in order to assess the im-
pact of isolated or combined treatment with esomeprazoleand chemotherapeutics on cell survival. In addition cells
were lysed using TRIzol® reagent (Invitrogen Life Tech-
nologies, NY, USA) according to the instructions of the
manufacturer, and stored at −80°C for later RNA process-
ing as described previously [10].
Measurement of intra- and extracellular pH
Intracellular pH (pHi) was measured using video imaging
techniques and the fluorescent pH indicator (2-carbox-
yethyl)-5- carboxyfluorescein (BCECF)-AM (Molecular
Probes, Eugene, OR, USA) according to the manufac-
turer’s protocol. Briefly, the pH value of solution A was
adjusted to 7.43, 7.05 and 6.50 and the pH value of solu-
tion B was adjusted to 7.4. Nigericin was diluted with
ddH2O at 5 mM (3.375 mg Nigericin:1 ml ddH2O).
1 μl Nigericin solution was added into 1 ml solution
A with the final concentration of 5 mM. BCECF-AM
pH-sensitive fluorescent probe was diluted into 5 mM
with DMSO and stored at −20°C away from light. Cells
were cultured for 24, 48 or 72 hours on glass-bottom-
dishes (35 mm diameter, Greiner Bio-One) with and with-
out esomeprazole (LD50), at a density of 1×105 cells per
dish for KYSE410 and 3,8x105 cells per dish for OE19, in
cell culture medium as mentioned above. Then, the
medium was replaced with 2 ml solution B and the cells
were incubated in a humidified atmosphere containing 5%
CO2 at 37°C. 2.5 μg/ml BCECF was added directly to the
dishes and cells were incubated for 5 minutes. Thereafter,
the glass bottom dish was continuously superfused with
37°C HEPES-buffered Ringer solution. pHi was measured
using BCECF fluorescence. BCECF was excited with light
of 440 nm and 490 nm wavelengths. The emitted fluores-
cence intensities were measured at 37°C in intervals of
25 seconds and monitored at the 500 nm wavelength
using a Photometrics camera (CoolSnapfx, Visitron Sys-
tems, Puchheim, Germany). A high-speed polychromator
system (Visichrome, Visitron Systems) was used to gener-
ate the different wavelengths. Polychromator and data ac-
quisition were controlled by the software MetaFluor
(Visitron Systems). Finally the measurements of each ex-
periment were calibrated by successively replacing the
HEPES-buffered Ringer solution with modified Ringer so-
lutions of pH 7.4, 7.0 and 6.5, each containing 10 μmol/l
Nigericin (Sigma-Aldrich), to determine the pHi. Per glass
bottom dish, the pHi of at least 20 single cells within
the field of view was measured. Three independent ex-
periments were performed with KYSE410 and OE19,
respectively.
For extracellular pH measurement cells were grown in
6 well plates (Sarstedt) at an initial density of 1.9 × 105
(KYSE410) or 3.8 × 105 (OE19) viable cells per flask for
72 hours during esomeprazole pre-treatment (LD50).
Extracellular pH (pHe) of the culture medium was then
measured after 72 hours of PPI treatment by pH211
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Mettler Toledo, Germany).
Analysis of changes in expression of resistance-relevant
miRNAs after PPI treatment
For assessment of a potential impact of PPI treatment
on miRNA expression, 18 miRNA were selected from
our own previous work (manuscript accepted). Briefly,
we conducted experiments with cisplatin- and 5-FU re-
sistant EAC and SCC cell lines and investigated the
miRNA expression pattern of these resistant cell lines.
From the miRNAs that showed differential expression
between resistant and sensitive cell lines, we then se-
lected 18 miRNA candidates that, according to current
literature, have an important impact on chemotherapy re-
sistance in cancer cells. For the purpose of this study, we
refer to these miRNAs as “resistance-relevant”. Namely,
we selected miR-16, miR-21, miR-23a, miR-24, miR-26a,
miR-106, miR-141, miR-155, miR-196a, miR-200a, miR-
200b, miR-200c, miR-221, miR-222, miR-296-5p, miR-
376a, miR-429 and let-7i for this study.
The miScript PCR system (Qiagen, Germany) was then
used to analyze miRNA expression of the resistance re-
levant miRNA candidates after PPI treatment (LD50).
miScript assays were performed according to the manu-
facturer’s instructions. Briefly, for each sample, 500 ng of
DNase pre-treated RNA was used for reverse transcrip-
tion into cDNA. Following the manufacturer’s protocol,
we utilized 4 μl miScript 5X RT Buffer, 1 μl Reverse
Transcriptase and 5 μl nuclease-free water. Incubation
of reagents was performed in a thermocycler (protocol:
60 minutes at 37°C, 5 minutes at 95°C, then a hold at
4°C). For real-time PCR, 2 μl of cDNA was mixed with
10 μl QuantiTect SYBR, 2 μl 10X miScript Universal
Primer, 2 μl gene specific 10X miScript Primer Assay,
and 4 μl nuclease-free water. All samples were assayed
in triplicate reactions using a BioRad CFX 384 Real-
Time System (Hercules/California USA). QuantitativeFigure 1 Dose–response curve of PPI treatment in esophageal cancer
treatment with esomeprazole on tumour cell survival in SCC (A) and EAC (analysis was performed using Bio-Rad CFX Manager 2.1.
MiRNA expression data were normalized to the ex-
pression levels of SNORD25, SNORD44 and SNORD68,
which displayed comparable expression across the differ-
ent groups (data not shown).
Statistical analysis
All data are means ± standard deviation unless otherwise
stated. The relative cell survival after PPI treatment (via-
bility assay) and after treatment with anticancer drugs
was calculated by normalizing the mean corrected ab-
sorbance of the treated cells to the corresponding un-
treated controls (given in%). For assessment of the effect
of PPI treatment on sensitivity to chemotherapy, the
relative survival of the negative controls was then be set
to “0”, and the effect of pre-treatment was presented as
relative survival of treated cells compared to negative
controls (given in%). Data were assessed for statistical
significance using parametric (Student’s t-test for equal
and unequal variances) tests as appropriate. P <0.05 was
considered to be statistically significant. All analyses
were performed using SPSS 20.0 (SPSS, Chicago, IL).
Results
Esomeprazole inhibits survival of esophageal cancer
cell lines
At first, we aimed to assess if esomeprazole impacts on
survival of esophageal cancer cell lines. Figure 1 presents
an overview of the dose–response curves of PPI treat-
ment with esomeprazole at various doses in SCC (A)
and EAC (B) cell lines. In both tumour subtypes, in-
creasing esomeprazole doses were dose-dependently as-
sociated with decreasinging cell survival with increasing
esomeprazole doses, thus providing evidence for a nega-
tive impact of PPI treatment on tumour cell survival. In
this context, sublethal doses were approximately 50 μM
in both cell lines, and LD50 of SCC and EAC cells were
250 μM and 200 μM, respectively.cell lines. The figure presents an overview of the impact of PPI
B) cells. PPI: proton pump inhibitor esomeprazole.
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esophageal cancer cell lines
Adhesion and migration are key determinants of the abi-
lity of tumour cells to metastasize into distant organs, as
metastasis includes invasion of circulating tumour cells
into distant organs where the tumour cells have to adhere
and migrate through the endothelium of the vessels. We
therefore investigated the impact of esomeprazole treat-
ment on adhesion and migration in esophageal cancer cell
lines. Figure 2 presents an overview of the results of adhe-
sion and migration assays performed on SCC (A) and
EAC (B) cell lines after PPI treatment with esomeprazole.
After 15, 30, 60 and 90 minutes of PPI treatment, the abil-
ity of tumour cells to adhere to coated wells under the
stimulation of TGF-β2 was significantly reduced in both
tumour entities compared to untreated controls (p ≤
0.025). Furthermore, the ability of tumour cells (SCC and
EAC) to migrate through 8-μm pores in a coated Boyden
Chamber was significantly reduced after PPI treatment
compared to controls (p < 0.0001).
Esomeprazole augments the cytotoxic effect of cisplatin
and 5-FU in esophageal cancer cell lines
Given the suppressive effect of esomeprazole on the sur-
vival and metastatic potential of esophageal cancer cells,
we were interested if esomeprazole might affect the sensi-
tivity of esophageal cancer cells towards commonly usedFigure 2 Effect of PPI treatment on metastatic potential of esophage
of PPI treatment on cell adhesion (1) and migration (2) in SCC (A) and EAC
with uncoated wells) were performed though for visual clarity they are not
inhibitor esomeprazole. Control: untreated control cells. *: statistically signifchemotherapeutic drugs such as cisplatin and 5-FU. We
therefore treated tumour cells with either esomeprazole
alone at different concentrations, or with cisplatin or 5-FU
at the respective LD50 concentrations, or with esomepra-
zole and chemotherapeutics together. Figure 3 presents an
overview of the impact of esomeprazole treatment on
otherwise untreated cells or on cells that were treated sim-
ultaneously with chemotherapeutics. Esomeprazole in
„sub-lethal dose“ did not impact on survival of untreated
or simultaneously chemotherapy treated SCC or EAC
cancer cells. Applied in „lethal“ or „highly lethal doses“,
however, esomeprazole reduced the survival of otherwise
untreated cells of both tumour entities (p < 0.05) as ex-
pected. Most interestingly, at these doses, esomeprazole
presented a significant additional cytotoxic effect on cells
treated with cisplatin or 5-FU in both SCC and EAC cells
(p < 0.05). However, this additional effect of esomeprazole
on the cytotoxicity of chemotherapeutics was higher in
cisplatin treated cells (resulting in an overall cytotoxicity
of 88-99% after combined treatment) than in 5 FU-treated
cells (resulting in an overall cytotoxicity of only about 80-
97% after combined treatment; p < 0.05).
Esomeprazole does not lead to intracellular acidification
and extracellular alkalisation in esophageal cancer cell lines
The literature suggests that PPIs mediate their effects
on tumour cells via disruption of the intra-extracellularal cancer cell lines. The figure presents an overview about the effect
(B) cell lines. Negative controls (i.e. adhesion and migration assays
included in the figures. PPI treatment: treatment with proton pump
icant different compared to control (p≤ 0.025).
Figure 3 Effect of PPI treatment on otherwise untreated cells and on CTX treated cells. Presents an overview of the impact of
esomeprazole treatment on otherwise untreated cells or on cells that were treated simultaneously with chemotherapeutics (3A: SCC; 3B: EAC).
Tumour cells were treated with either esomeprazole alone at different concentrations (50 μM: “sub-lethal”, 86-100% cell survival; 250 μM: “lethal”,
20-30% cell survival; 350 μM: “highly lethal”, <10% cell survival), or with cisplatin or 5-FU at the respective LD50 concentrations, or with esomeprazole
and chemotherapeutics together. The upper graphs present an overview of the relative cell survival of the respective groups (PPI treated cells versus
chemotherapy (CTX) treated cells versus PPI + CTX treated cells). The lower graphs present an overview about the additional cytotoxic
effect of PPI treatment on otherwise untreated cells (PPI w/o CTX) or on CTX treated cells (PPI w CTX). PPI: proton pump inhibitor esomeprazole. CTX:
chemotherapy. *: statistically significant different compared to control.
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of cancer cells. We hypothesized that the observed sup-
pressive effect of esomeprazole on cell survival, metastatic
potential and sensitivity towards cisplatin and 5-FU in
both esophageal cancer subtypes might be caused by in-
tracellular acidification/extracellular alkalisation. There-
fore, we investigated the intracellular pH in both tumour
subtypes, and the proton concentration in the extracellu-
lar space (culture medium). We could not detect any dif-
ferences in the intracellular pH between cells that were
exposed to esomeprazole (LD50) for 24/48 hours and un-
treated controls. However, surprisingly, the intracellular
pH was significantly higher in cells (SCC and EAC) trea-
ted with esomeprazole for 72 hours compared to untrea-
ted controls (p ≤ 0.017). In addition, the concentration of
protons was significantly higher in the extracellular space
of esomeprazole treated cells (72 hours, LD50) compared
to untreated controls (p ≤ 0.001) (see Figures 4 and 5).
Esomeprazole affects expression of resistance-relevant
miRNAs
miRNAs are important epigenetic regulators of tu-
mour cell survival, metastatic potential and sensitivity
towards chemotherapeutic drugs. We hypothesized thatesomeprazole might mediate its effects on these factors
via regulation of miRNAs. Therefore, we selected 18
miRNAs that we previously found to be resistance-
relevant, and assessed their expression pattern in esome-
prazole treated cells and untreated controls. From these
18 miRNAs, 14 candidates were expressed at detectable
levels in the tumour cells. After PPI treatment, we ob-
served significant deregulation of 8 of these miRNAs in
SCC cells and 9 of these miRNAs in EAC cells. Most
interestingly, 3 of these resistance-relevant miRNA candi-
dates showed a similar pattern of deregulation in both
tumour types: miR-141 and miR-200b were significanty
upregulated whereas miR-376a was significantly down-
regulated (see Table 1 and Figure 6).
Discussion
The overall prognosis of esophageal cancer patients re-
mains very poor. However, conservative treatment op-
tions, especially neoadjuvant radiochemotherapy, have
been widely adopted because they provide a benefit for
overall survival in patients with locally advanced disease
and good response to neoadjuvant treatment [3-6,8,9].
However, only a subset of patients presents a major re-
sponse to radiochemotherapy, and only these patients
Figure 4 Effect of PPI treatment on intracellular pH. The figure presents the results of intracellular pH measurement after 24/48/72 hours of
esomeprazole treatment (LD50) in SCC (A) and EAC (B) cells. PPI treatment: treatment with esomeprazole. *: statistically significant different
compared to control (p ≤ 0.017).
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This problem highlights the urgent need for new treat-
ment options, either as first-line treatment, or as additive
treatment to conservative therapies that improves the ef-
fect of radiochemotherapy. In this context, proton pump
inhibitors (PPIs) might provide a new tool for treatment
of esophageal cancer. Based on the highly promising re-
sults in other tumour entities [19,23-25], we hypothesized
that PPIs might impact on tumour cell survival, meta-
static potential and chemotherapy resistance in esophageal
cancer.
Our data provide the first evidence that the proton
pump inhibitor esomeprazole has cytotoxic effects on
esophageal cancer cell lines, by suppressing cell survival
of SCC and EAC cell lines, in a dose-dependent manner.
Furthermore, we found that esomeprazole inhibits ad-
hesion and migration, two key aspects of tumour me-
tastasis, in SCC and EAC cell lines. This supports theFigure 5 Effect of PPI treatment on extracellular proton concentration
space (culture medium) after 72 hour PPI treatment (LD50) in SCC (A) and
control (p≤ 0.001).conclusion that PPIs reduce the metastatic potential of
esophageal cancer cells. We also demonstrated that eso-
meprazole has an additive effect on the cytotoxicity of
the commonly used chemotherapeutics, cisplatin and
5-FU, in both histological subtypes. Taken together, our
results demonstrate for the first time that PPIs such as
esomeprazole have an effect on tumour cell survival,
metastatic potential and sensitivity towards different
chemotherapeutics in esophageal cancer cell lines, as
has previously been reported in other tumour entities.
This highlights their potential use as first-line treat-
ment option or additive therapy in combination with
chemotherapy in esophageal cancer patients.
On the search for cellular mechanisms that mediate
the effect of esomeprazole on esophageal cancer cells,
we first focussed on the potential of PPIs to disrupt the
intra-extracellular pH gradient. This was described as the
main mechanism of action of PPIs in other malignancies. The figure presents the concentration of protons in the extracellular
EAC (B) cells. *: statistically significant different compared to
Table 1 Effect of PPI treatment on expression of
resistance-relevant miRNAs
miRNAs SCC EAC
miR-16 −1,26 ± 0,12 /
miR-23a / +1,51 ± 0,20
miR-24 / +1,47 ± 0,17
miR-26a / +1,97 ± 0,3
miR-106 −1,43 ± 0,14 /
miR-141 +1,19 ± 0,07 +1,49 ± 0,16
miR-155 −1,45 ± 0,09 /
miR-200a / +1,35 ± 0,05
miR-200b +1,18 ± 0,08 +1,25 ± 0,11
miR-200c / +1,59 ± 0,09
miR-221 −1,58 ± 0,17 /
miR-222 −1,31 ± 0,26 /
miR-296-5p / −1,31 ± 0,29
miR-376a −1,34 ± 0,16 −1,55 ± 0,08
The table presents an overview of the significant deregulation/fold-change in
expression of selected miRNAs in SCC and EAC cells after treatment with
esomeprazole (LD50) compared to controls. +: significant upregulation.
-: significant downregulation.
Lindner et al. Journal of Experimental & Clinical Cancer Research 2014, 33:73 Page 8 of 12
http://www.jeccr.com/content/33/1/73such as prostate cancer [23], breast cancer [24], colon can-
cer [26] and ovarian cancer [26]. However, most surpris-
ingly, we detected that esomeprazole treatment led to an
intracellular increase of pH in both SCC and EAC cells
after 72 hour of treatment. Furthermore, the concen-
tration of extracellular protons was higher after 72 hour
PPI treatment compared to untreated controls. ThisFigure 6 Effect of PPI treatment on expression of resistance-relevant
deregulation of selected miRNAs in SCC and EAC cells in after treatment with
upregulation. ⬇: significant downregulation.observation does not support the hypothesis that in
esophageal cancer cells, PPIs mediate their effects mainly
via inhibition of membrane based proton pumps and sub-
sequent acidification of the intracellular space and alkali-
sation of extracellular space. In contrast, our experiments
suggested that PPI treated cells were still able to eliminate
protons from the intracellular space and to (at least in
part) excrete them into the extracellular compartment.
Therefore, we hypothesized that esomeprazole might me-
diate its impact on esophageal cancer cells via epigenetic
regulation. We found that esomeprazole treatment leads
to deregulation of a number of chemotherapy resistance-
relevant miRNAs. Specifically, PPI treatment led to upreg-
ulation of miR-141 and miR-200b and downregulaton of
miR-376a in SCC and EAC cells.
Our results on the effects of the PPI ,esomeprazole, on
tumour cell survival, metastasis and chemotherapy re-
sistance in esophageal cancer are supported by current
literature on other tumour entities. For example, it was
described that proton pump inhibitors can induce apop-
tosis or inhibit tumour cell growth in gastric or hepato-
blastoma cancer cell lines but not in non-tumourous
primary cells at high concentrations [27,28]. Oral ad-
ministration of a small molecule inhibitor of V-ATPase,
NiK-12192, was reported to cause a significant inhibition
of formation of spontaneous metastases of a human lung
tumours in nude mice [31]. Furthermore, several studies
reported that V-ATPases are involved in tumour inva-
sion and multi-drug-resistance in many types of cancer
[16-22]. In addition, a number of authors demonstrated
an effect of PPIs or other V-ATPase inhibitors on cancermiRNAs. The figure presents an overview about the significant
esomeprazole (LD50) for 72 hours, compared to controls. ⬆: significant
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sensitivity of colon adenocarcinoma derived cells towards
chemotherapeutic drugs [32], or specific inhibitors of V-
ATPase were demonstrated to impair the preferential ac-
cumulation of daunomycin in lysosomes and to reverse
the resistance towards anthracyclines in drug-resistant
renal epithelial cells [33]. In a screening study of small
molecules that disturbed the anti-apoptotic function of
Bcl-2 or Bcl-xL, Sasazawa and coworkers found that V-
ATPase inhibitors such as bafilomycin A1 were able to
induce apoptosis in drug resistant cells following treat-
ment with taxol [34]. Further evidence for the role of V-
ATPases in chemoresistance was reported from targeted
molecular studies: small interfering RNA against the
ATP6L subunit of proton pump V-ATPase was shown
to attenuate chemoresistance of breast cancer cells [16]
and hepatocellular carcinoma xenografts [20].
Regarding the effect of PPI treatment on intra- and
extracellular pH, our data are somewhat contradictory to
most reports in the current literature. Tumours were re-
ported to present an intracellular pH ranging from 7.12
to 7.56 (pHi of normal cells: 6.99-7.20), and an extracel-
lular pH of 6.2-6.9 (pHe of normal extracel- lular space:
7.3-7.4), which is controlled by key pH regulators that
maintain a neutral/alkaline intracellular pH by eliminat-
ing lactate or protons. Extracellular acidity in tumours
tends to be associated with a poorer prognosis based on
its effect on aggressiveness, metastasis and resistance to-
wards chemotherapy and radiotherapy treatment [35].
Proton pumps such as V-H ATPases play a key role in
the control of the intra-extracellular pH-gradient. These
pumps are ATP-dependent membrane-based transporters
that control pHi and pHe by actively transport protons
from the cytoplasmic compartment to the extracellular
space or into other intracellular vesicles [36]. Conse-
quently, inhibition of proton pumps via PPIs should im-
pair the ability of the cell to eliminate protons from the
intracellular space, subsequently leading to an accumula-
tion of protons in the cytosol of the cells with a decrease
of pHi, and an increase of pHe. And in fact, Chen et al.
observed a decrease of pHi and an increase of pHe in a
human gastric cell line after PPI treatment [32]. Moreover,
Luciani and colleagues demonstrated that PPI pretreat-
ment of melanoma, colon adenocarcinoma, breast cancer
and ovarian carcinoma cell lines was associated with an
increase of both, pHe and the pH of lysosomal organelles
[26]. Furthermore, there is some evidence in the current
literature that changes in pHi and pHe impact on prog-
nosis [37], invasiveness and metastasis formation [38], ac-
tivation of extracellular metalloproteases that influence
tumour cell motility, proliferation and metastasis [23],
and resistance towards irradiation and chemotherapy
drugs [35]. For example, acidic pHe in tumours can
lead to an extracellular accumulation of weakly basicchemotherapeutics such as anthracyclines, anthraquinones
and vinca alkaloid which subsequently fail to reach their
intracellular targets. Thus, an increased extracellular acid-
ity in tumours can promote multi drug resistance [23-25].
In contrast to these reports, we found that pHi in-
creased and pHe decreased after PPI treatment in esopha-
geal cancer cell lines. We acknowledge that this different
effect of PPI treatment on pHi and pHe might be influ-
enced by specific biological characteristics which separate
esophageal cancer from other tumour entities. However,
our data provide the first reported evidence that in eso-
phageal cancer cell lines, PPI treatment does not lead to
an intracellular accumulation of protons and an inability
to eliminate protons in the extracellular compartment.
Our data suggest that the observed effect of PPI treatment
in our study might at least in part not be mediated by the
inhibition of proton pumps.
Regarding a potential effect of PPI treatment on ex-
pression of miRNAs, our study shows for the very first
time that esomeprazole treatment impacts on expression
of resistance-relevant miRNAs. There are no prior re-
ported studies that investigate the potential of PPIs to
alter miRNA expression in either SCC or EAC. Most
interestingly, we found three miRNAs (namely miR-141,
miR-200b and miR-376a) to be deregulated in a similar
fashion in both tumour subtypes, implying that these
miRNAs might in general be affected by PPI treatment.
Furthermore, all three miRNAs have been previously de-
scribed to impact on tumour cell survival and chemo-
therapy resistance in various cancer types. Imanaka et al.
reported that miR-141 was highly expressed in cisplatin-
resistant SCC cell lines [39], and van Jaarsveld and col-
leagues found an association between miR-141 levels and
response to cisplatin therapy in ovarian cancer patients
[40]. In addition, elevated miR-200b levels were described
to influence cell proliferation, invasion and migration in
gastric cancer [41], and the development of multi drug re-
sistance in Ehrlich asites cell lines [42]. In prostate cancer
cells, miR-376 was shown to be involved in regulation of
proliferation, apoptosis, migration and cell invasion [43].
Furthermore, this miRNA was also found to be involved
in multi drug resistance [44].
There are a few limitations of the current study that
have to be considered for proper interpretation of our
results. Firstly, the current study represents an in-vitro
study with only one esophageal adenocarcinoma and
one squamous cell carcinoma cell line. This means that
our data cannot be immediately transferred into clinical
settings, as results might be limited to the selected cell
lines and reproducibility might be limited. However,
this is the first study that investigates the effect of
PPI treatment on esophageal cancer, and we selected
well known and commonly used esophageal cancer cell
lines. Therefore, in our opinion this data provides a valid
Lindner et al. Journal of Experimental & Clinical Cancer Research 2014, 33:73 Page 10 of 12
http://www.jeccr.com/content/33/1/73basis for further investigations in additional in-vitro or in-
vivo experiments. Secondly, we used esomeprazole doses
of up to 250 μM in our experiments. In this context, max-
imal tissue concentrations after esomeprazole administra-
tion in humans have to be considered in order to achieve
clinically relevant data on the effect of esomeprazole on
tumour characteristics. Based on product information
from Astra Zeneca, 40 mg i.v. esomeprazole (which is the
standard dose of esomprazole per day in the therapy of
peptic ulcer and gastritis) would achieve a steady state tis-
sue concentration of 6 μM for an 80 kg human. However,
in specific situations such as hypersecretory conditions,
recommended adult oral starting dose of esopmeprazole is
60 mg once daily with subsequent adjustment of individ-
ual doses, and doses up to 120 mg three times daily have
been administered. The doses used in our experiments are
higher than the currently clinically used doses. However,
PPIs are considered to be generally safe in application.
Despite some reported adverse side effects such as osteo-
porosis and bone fracture, hypomagnesaemia, the devel-
opment of gastric polyps, enteric infections, interstitial
nephritis and pneumonia, and the absolute risk of compli-
cations attributed to PPIs is low [45]. Moreover, the doses
used in our experiments are similar to those of other re-
search groups [14]. Thirdly, we did not include an analysis
of the expression pattern of proton pumps in the cell
membrane or in membranes of intracellular vesicles, or of
the exact percentage and strength of inhibition of the pro-
ton pumps via esomeprazole. We only analysed the intra-
and extracellular pH and concluded from these data that
both cell lines were still able to excrete protons into the
extracellular space. However, as several other authors ob-
served that PPI treatment lead to intracellular acidifica-
tion, in our opinion the absence of this accumulation of
protons in the intracellular space in our experiments justi-
fies the conclusion that this is not the main effect of action
of esomeprazole in esophageal cancer cell lines. Finally,
we selected a number of resistance-relevant miRNAs from
our previous experiments on drug resistant cell lines, and
did not include screening of general miRNA expression
pattern after PPI treatment, or target validation. This ap-
proach would allow a more sophisticated interpretation of
the effect of PPI treatment on miRNA expression. How-
ever, our experiments aimed to simply investigate if
miRNA deregulation caused by PPI treatment might be a
potential mechanism for the impact of PPI treatment on
cancer cells. We showed that esomeprazole altered ex-
pression of a number of miRNAs that are well known to
impact on tumour cell survival and drug resistance in the
current literature.
Conclusion
The current study provides for the very first time evidence
that PPIs impact on tumour cell survival, metastaticpotential and sensitivity towards chemotherapeutic drugs
in esophageal cancer cell lines, as has previously been
demonstrated in other malignancies. Unexpectedly, we
observed that in esophageal cancer cell lines PPI treat-
ment does not lead to intracellular acidification and extra-
cellular alkalisation, factors previously described, in other
tumour entities, as a potential mechanism for decreased
aggressiveness and drug resistance of tumours after PPI
treatment. Most interestingly, we found, that the expres-
sion of resistance-relevant miRNAs in esophageal cancer
cells (SCC and EAC) is affected by PPI treatment. miR-
NAs are key players in the epigenetic control of global
gene expression, and the effect of PPIs on miRNA expres-
sion which we observed may be a previously unrecognised
mechanism of PPI action on tumours. Our study provides
an important step towards developing a new therapeutic
approach for esophageal cancer, especially as PPIs are
already widely used in the clinic and do not exhibit major
side effects. However, further in-vitro and in-vivo expe-
riments are needed to determine if PPIs can be used
as either first-line treatment or additive therapy in eso-
phageal cancer patients.
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